Ceftazidime-Avibactam Susceptibility Breakpoints against Enterobacteriaceae and Pseudomonas aeruginosa

Clinical susceptibility breakpoints against Enterobacteriaceae and Pseudomonas aeruginosa for the ceftazidime-avibactam dosage regimen of 2,000/500 mg every 8 h (q8h) by 2-h intravenous infusion (adjusted for renal function) have been established by the FDA, CLSI, and EUCAST as susceptible (MIC, ≤8...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Antimicrob Agents Chemother
Главные авторы: Nichols, Wright W., Stone, Gregory G., Newell, Paul, Broadhurst, Helen, Wardman, Angela, MacPherson, Merran, Yates, Katrina, Riccobene, Todd, Critchley, Ian A., Das, Shampa
Формат: Artigo
Язык:Inglês
Опубликовано: American Society for Microbiology 2018
Предметы:
Clinical Therapeutics
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6201065/
https://ncbi.nlm.nih.gov/pubmed/30061279
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.02590-17
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы